Results 61 to 70 of about 5,389 (186)

NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases

BMC Cancer, 2023
Background The optimal treatment strategy for resectable BRAF V600E mutant colorectal oligometastases (CRM) has not been established due to the rarity and rapid progression of the disease.
Shin Kobayashi, Hideaki Bando, Akinobu Taketomi, Takeshi Takamoto, Eiji Shinozaki, Manabu Shiozawa, Hiroki Hara, Kentaro Yamazaki, Koji Komori, Nobuhisa Matsuhashi, Takeshi Kato, Yoshinori Kagawa, Mitsuru Yokota, Eiji Oki, Keigo Komine, Shinichiro Takahashi, Masashi Wakabayashi, Takayuki Yoshino   +17 more
doaj   +1 more source

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 802-811, March 2026.
A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function.
Michael I. Sponfeldner, Pauline Dürr, Phyllis Lensker, Katja Gessner, Lisa Cuba, Rainer Fietkau, Markus F. Neurath, Bernd Wullich, Marianne Pavel, Carola Berking, Matthias W. Beckmann, Andreas Mackensen, Frank Dörje, Martin F. Fromm   +13 more
wiley   +1 more source

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC [PDF]

, 2022
Colorectal cancer; Encorafenib; Quality of lifeCáncer colorrectal; Encorafenib; Calidad de vidaCàncer colorectal; Encorafenib; Qualitat de vidaBackground In the BEACON CRC study (NCT02928224), encorafenib plus cetuximab with binimetinib {9.3 versus 5.9 ...
Grothey, Axel, Kopetz, Scott, Tabernero Caturla, Josep, Van Cutsem, Eric, Wasan, Harpreet, Yaeger, Rona, Yoshino, Takayuki   +6 more
core   +1 more source

Deep Dermal and Subcutaneous Deposits in Thin Melanoma: A Cautionary Tale

Journal of Cutaneous Pathology, Volume 53, Issue 3, Page 224-229, March 2026.
ABSTRACT Melanoma microsatellites are peritumoral metastatic deposits and surrogates for potentially aggressive biological behavior. Their presence indicates clinical stage III disease. They are rarely reported in association with thin primary tumors (< 1.0 mm, pT1).
Angela Cheng, Jennette Gruchy, Ariel Burns, Richard Langley, Jason Williams, Ryan DeCoste   +5 more
wiley   +1 more source

Precision medicine in cutaneous melanoma—A comprehensive review

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 3, Page 377-386, March 2026.
Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley   +1 more source

Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration

Advanced Science, Volume 13, Issue 12, 27 February 2026.
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély, István Narozsny, Levente Szarka, Daniel V. Veres, Peter Csermely, Dávid Keresztes   +5 more
wiley   +1 more source

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. [PDF]

, 2019
PurposeDiarrhea is recognized as a common adverse event associated with tyrosine kinase inhibitors (TKIs), with those targeting the ErbB family of receptors being associated with the highest rate of diarrhea.MethodsThis paper reviews data on the ...
Bosserman, Linda, Bryce, Richard, Di Palma, Jack A, Moran, Susan, Olek, Elizabeth, Rugo, Hope S, Tripathy, Debu   +6 more
core  

Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis [PDF]

, 2022
Background: The objective of this study was to estimate the relative efficacy and safety of targeted therapies for the treatment of metastatic melanoma using a network meta-analysis (NMA).
Berardi R, Corrie P, Guidoboni M, Kolovos S, Laramée P., Macabeo B, Meyer N, Schlueter M, Trouiller JB   +8 more
core   +1 more source

Encorafenib plus cetuximab for the treatment of -mutated metastatic colorectal cancer

Therapeutic Advances in Gastroenterology, 2022
B-type RAF ( BRAF ) -V600E mutations in metastatic colorectal cancer (mCRC) have been described in up to 12% of the patients. This mutation confers a bad prognostic and poor response with standard chemotherapy.
Javier Ros, Nadia Saoudi, Iosune Baraibar, Francesc Salva, Josep Tabernero, Elena Elez   +5 more
doaj   +1 more source

Encorafenib (Braftovi)

Canadian Journal of Health Technologies, 2021
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire   +3 more sources